Genetic testing in medullary thyroid carcinoma syndromes: Mutation types and clinical significance

Hassan M. Heshmati, Hossein Gharib, Sundeep Khosla, Haitham S. Abu-Lebdeh, Noralane Morey Lindor, Stephen N Thibodeau

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To determine the types of mutations and the clinical significance of a specific genotype in familial medullary thyroid carcinoma (MTC) syndromes. Design: We retrospectively and prospectively studied patients with MTC at a tertiary referral center. Material and Methods: The study cohort consisted of 348 affected patients and at-risk family members of MTC kindreds, including 33 multiple endocrine neoplasia type IIA (MEN IIA) kindreds with 165 members, 13 familial MTC alone (FMTC) kindreds (at least 4 affected members with MTC per kindred, without evidence of pheochromocytoma and hyperparathyroidism) with 108 members, 15 'other hereditary MTC' kindreds (2 or 3 affected members) with 42 members, and 33 individuals with sporadic MTC. An additional 53 subjects from the aforementioned MEN IIA kindreds who were clinically affected but not genetically tested were also included in an analysis of the relationship between genotype and phenotype. The presence of germline mutations in the RET protooncogene was studied by DNA sequence analysis of exons 10, 11, and 13. Results: Germline RET mutations in exons 10 and 11 were identified in 32 of 33 MEN IIA kindreds (97%), 10 of 13 FMTC kindreds (77%), and 10 of 15 'other hereditary MTC' kindreds (67%). No mutations were identified in exon 13. No patient with sporadic MTC had a germline mutation. In MEN IIA, codon 634 was affected in 73% of the kindreds, whereas in FMTC, the main affected codon was codon 618 (54%). In MEN IIA, patients with codon 634 mutations had a higher risk of having C-cell disease, pheochromocytoma, and hyperparathyroidism than did those with other mutations (P<0.05, P<0.001, and P<0.01, respectively). Conclusion: RET analysis is a reliable, practical, and cost-effective test in the screening of at-risk family members of MEN IIA and FMTC kindreds. In addition, RET analysis may be helpful in the follow-up of gene carriers and for the early detection of pheochromocytoma and hyperparathyroidism in patients with codon 634 mutations.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalMayo Clinic Proceedings
Volume72
Issue number5
StatePublished - 1997

Fingerprint

Multiple Endocrine Neoplasia
Genetic Testing
Codon
Mutation
Germ-Line Mutation
Hyperparathyroidism
Pheochromocytoma
Exons
Genotype
Medullary Thyroid cancer
DNA Sequence Analysis
Tertiary Care Centers
Cohort Studies
Phenotype
Costs and Cost Analysis
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic testing in medullary thyroid carcinoma syndromes : Mutation types and clinical significance. / Heshmati, Hassan M.; Gharib, Hossein; Khosla, Sundeep; Abu-Lebdeh, Haitham S.; Lindor, Noralane Morey; Thibodeau, Stephen N.

In: Mayo Clinic Proceedings, Vol. 72, No. 5, 1997, p. 430-436.

Research output: Contribution to journalArticle

@article{69503aa44efd48bba8edbcfc8e31f301,
title = "Genetic testing in medullary thyroid carcinoma syndromes: Mutation types and clinical significance",
abstract = "Objective: To determine the types of mutations and the clinical significance of a specific genotype in familial medullary thyroid carcinoma (MTC) syndromes. Design: We retrospectively and prospectively studied patients with MTC at a tertiary referral center. Material and Methods: The study cohort consisted of 348 affected patients and at-risk family members of MTC kindreds, including 33 multiple endocrine neoplasia type IIA (MEN IIA) kindreds with 165 members, 13 familial MTC alone (FMTC) kindreds (at least 4 affected members with MTC per kindred, without evidence of pheochromocytoma and hyperparathyroidism) with 108 members, 15 'other hereditary MTC' kindreds (2 or 3 affected members) with 42 members, and 33 individuals with sporadic MTC. An additional 53 subjects from the aforementioned MEN IIA kindreds who were clinically affected but not genetically tested were also included in an analysis of the relationship between genotype and phenotype. The presence of germline mutations in the RET protooncogene was studied by DNA sequence analysis of exons 10, 11, and 13. Results: Germline RET mutations in exons 10 and 11 were identified in 32 of 33 MEN IIA kindreds (97{\%}), 10 of 13 FMTC kindreds (77{\%}), and 10 of 15 'other hereditary MTC' kindreds (67{\%}). No mutations were identified in exon 13. No patient with sporadic MTC had a germline mutation. In MEN IIA, codon 634 was affected in 73{\%} of the kindreds, whereas in FMTC, the main affected codon was codon 618 (54{\%}). In MEN IIA, patients with codon 634 mutations had a higher risk of having C-cell disease, pheochromocytoma, and hyperparathyroidism than did those with other mutations (P<0.05, P<0.001, and P<0.01, respectively). Conclusion: RET analysis is a reliable, practical, and cost-effective test in the screening of at-risk family members of MEN IIA and FMTC kindreds. In addition, RET analysis may be helpful in the follow-up of gene carriers and for the early detection of pheochromocytoma and hyperparathyroidism in patients with codon 634 mutations.",
author = "Heshmati, {Hassan M.} and Hossein Gharib and Sundeep Khosla and Abu-Lebdeh, {Haitham S.} and Lindor, {Noralane Morey} and Thibodeau, {Stephen N}",
year = "1997",
language = "English (US)",
volume = "72",
pages = "430--436",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Genetic testing in medullary thyroid carcinoma syndromes

T2 - Mutation types and clinical significance

AU - Heshmati, Hassan M.

AU - Gharib, Hossein

AU - Khosla, Sundeep

AU - Abu-Lebdeh, Haitham S.

AU - Lindor, Noralane Morey

AU - Thibodeau, Stephen N

PY - 1997

Y1 - 1997

N2 - Objective: To determine the types of mutations and the clinical significance of a specific genotype in familial medullary thyroid carcinoma (MTC) syndromes. Design: We retrospectively and prospectively studied patients with MTC at a tertiary referral center. Material and Methods: The study cohort consisted of 348 affected patients and at-risk family members of MTC kindreds, including 33 multiple endocrine neoplasia type IIA (MEN IIA) kindreds with 165 members, 13 familial MTC alone (FMTC) kindreds (at least 4 affected members with MTC per kindred, without evidence of pheochromocytoma and hyperparathyroidism) with 108 members, 15 'other hereditary MTC' kindreds (2 or 3 affected members) with 42 members, and 33 individuals with sporadic MTC. An additional 53 subjects from the aforementioned MEN IIA kindreds who were clinically affected but not genetically tested were also included in an analysis of the relationship between genotype and phenotype. The presence of germline mutations in the RET protooncogene was studied by DNA sequence analysis of exons 10, 11, and 13. Results: Germline RET mutations in exons 10 and 11 were identified in 32 of 33 MEN IIA kindreds (97%), 10 of 13 FMTC kindreds (77%), and 10 of 15 'other hereditary MTC' kindreds (67%). No mutations were identified in exon 13. No patient with sporadic MTC had a germline mutation. In MEN IIA, codon 634 was affected in 73% of the kindreds, whereas in FMTC, the main affected codon was codon 618 (54%). In MEN IIA, patients with codon 634 mutations had a higher risk of having C-cell disease, pheochromocytoma, and hyperparathyroidism than did those with other mutations (P<0.05, P<0.001, and P<0.01, respectively). Conclusion: RET analysis is a reliable, practical, and cost-effective test in the screening of at-risk family members of MEN IIA and FMTC kindreds. In addition, RET analysis may be helpful in the follow-up of gene carriers and for the early detection of pheochromocytoma and hyperparathyroidism in patients with codon 634 mutations.

AB - Objective: To determine the types of mutations and the clinical significance of a specific genotype in familial medullary thyroid carcinoma (MTC) syndromes. Design: We retrospectively and prospectively studied patients with MTC at a tertiary referral center. Material and Methods: The study cohort consisted of 348 affected patients and at-risk family members of MTC kindreds, including 33 multiple endocrine neoplasia type IIA (MEN IIA) kindreds with 165 members, 13 familial MTC alone (FMTC) kindreds (at least 4 affected members with MTC per kindred, without evidence of pheochromocytoma and hyperparathyroidism) with 108 members, 15 'other hereditary MTC' kindreds (2 or 3 affected members) with 42 members, and 33 individuals with sporadic MTC. An additional 53 subjects from the aforementioned MEN IIA kindreds who were clinically affected but not genetically tested were also included in an analysis of the relationship between genotype and phenotype. The presence of germline mutations in the RET protooncogene was studied by DNA sequence analysis of exons 10, 11, and 13. Results: Germline RET mutations in exons 10 and 11 were identified in 32 of 33 MEN IIA kindreds (97%), 10 of 13 FMTC kindreds (77%), and 10 of 15 'other hereditary MTC' kindreds (67%). No mutations were identified in exon 13. No patient with sporadic MTC had a germline mutation. In MEN IIA, codon 634 was affected in 73% of the kindreds, whereas in FMTC, the main affected codon was codon 618 (54%). In MEN IIA, patients with codon 634 mutations had a higher risk of having C-cell disease, pheochromocytoma, and hyperparathyroidism than did those with other mutations (P<0.05, P<0.001, and P<0.01, respectively). Conclusion: RET analysis is a reliable, practical, and cost-effective test in the screening of at-risk family members of MEN IIA and FMTC kindreds. In addition, RET analysis may be helpful in the follow-up of gene carriers and for the early detection of pheochromocytoma and hyperparathyroidism in patients with codon 634 mutations.

UR - http://www.scopus.com/inward/record.url?scp=0031008810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031008810&partnerID=8YFLogxK

M3 - Article

C2 - 9146685

AN - SCOPUS:0031008810

VL - 72

SP - 430

EP - 436

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -